Cyteir Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Markus F. Renschler
- Full Time Employees
- 46
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 128 Spring Street Lexington MA United States of America 02421
- IPO Date
- Jun 18, 2021
- CIK
- 0001662244
- Website
- cyteir.com
- Similar Companies
- Business
- Cyteir Therapeutics, Inc., a biotechnology company that was previously in the clinical stage of development, is currently undergoing a process of complete liquidation and dissolution. The company had focused on pioneering precision oncology medicines designed to inhibit DNA damage repair. After a strategic review, Cyteir announced the discontinuation of all development activities for its investigational product candidates, including CYT-0851, which was undergoing Phase I/II clinical trials for solid tumors and hematologic malignancies, and its preclinical program, CYT-1853. The decision led to the company’s voluntary delisting from Nasdaq, effective in March 2024, and the filing of a Certificate of Dissolution with the Delaware Secretary of State around the same time. The company’s plan includes winding down operations, liquidating assets, and distributing remaining cash to its shareholders. Cyteir Therapeutics was established in 2012 and operated from Lexington, Massachusetts.
Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq
Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile
Cyteir: Although The Company Is Winding Down, The Lead Asset Had Promise
Cyteir Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights
Cyteir Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
Cyteir Therapeutics Announces Prioritization of CYT-0851 Development and Extended Cash Runway
Global Sepsis And Septic Shock Treatment Market Report 2022-2030: Expected Launch of Pipeline Drugs Such as MDX 1105, CYT-107, ALT-836, LB-1148, IFX-1 - ResearchAndMarkets.com
Cyteir Therapeutics Reports Third Quarter 2022 Financial Results and Operational Highlights
Cyteir Therapeutics Presents Poster on the Identification of Mechanism of Action of CYT-0851 at the 34th Annual EORTC-NCI-AACR Symposium
2022 US, UK and Japan Nontuberculous Mycobacteria Market Size and Trend Report to 2031 - Players Include Revimmune, Novartis, Insmed and Nobelpharma - ResearchAndMarkets.com
Cyteir Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
Cyteir Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
Cyteir Therapeutics Reports Second Quarter 2022 Financial Results and Operational Highlights
Cyteir Therapeutics, Inc. (CYT) CEO Dr. Markus Renschler on Q4 2021 Results - Earnings Call Transcript
Cyteir Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
Cyteir Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 16, 2022
Cyteir Therapeutics Selected to Join Russell 2000® Index
Cyteir Therapeutics to Participate in the 19th Annual Morgan Stanley Global Healthcare Conference
Cyteir Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference
Cyteir Therapeutics Announces Closing of Initial Public Offering